A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Trial ID or NCT#

NCT06655246

Status

recruiting iconRECRUITING

Purpose

In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.

Official Title

A Phase 1a/1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Minggui Pan, MD, PhD
Minggui Pan, MD, PhD
Medical oncologist, Sarcoma specialist
Clinical Professor, Medicine - Oncology
Nam Quoc Bui
Nam Quoc Bui
Medical oncologist, Sarcoma specialist
Clinical Associate Professor, Medicine - Oncology
Kristen N Ganjoo
Kristen N Ganjoo
Sarcoma specialist, Medical oncologist
Professor of Medicine (Oncology)

Contact us to find out if this trial is right for you.

Contact

Clinical Operations
858-500-8800

SEND MESSAGE

View on ClinicalTrials.gov